ALM-412

N/A

Report date: 2026/03/06 20:02:51
NME

Base Information

Drug NameALM-412
Drug Alias NameZKN013ZKN-013ALM-412ZKN-0013
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRibosome modulators
TargetsNot applicable
Therapy Area/IndicationsEpidermolysis Bullosa, JunctionalEpidermolysis Bullosa DystrophicaEpidermolysis Bullosa +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesZikani Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEloxx PharmaceuticalsAlmirall Sa
Inactive CompaniesN/A
Active IndicationsEpidermolysis Bullosa, JunctionalEpidermolysis Bullosa DystrophicaAdenomatous Polyposis Coli
Inactive IndicationsEpidermolysis Bullosa

Other Information

ATC CodeN/A
Related LinksN/A